-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JVxSQUaVR1/fyoSDv2wnPWrvxHRqNvlKfu1rEmC5n9yVSLl1eA2Bl5hv3EZklJKl QrzIHAGWgPR7wAdyTGbm4A== 0001104659-05-012747.txt : 20050324 0001104659-05-012747.hdr.sgml : 20050324 20050324171015 ACCESSION NUMBER: 0001104659-05-012747 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050318 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20050324 DATE AS OF CHANGE: 20050324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABGENIX INC CENTRAL INDEX KEY: 0001052837 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943248826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24207 FILM NUMBER: 05702673 BUSINESS ADDRESS: STREET 1: 6701 KAISER DRIVE CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 5106086500 MAIL ADDRESS: STREET 1: 6701 KAISER DRIVE CITY: FREMONT STATE: CA ZIP: 94555 8-K 1 a05-5667_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

        Date of report (Date of earliest event reported):     March 18, 2005

 

Abgenix, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

000-24207

 

94-3248826

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

6701 Kaiser Drive, Fremont California

 

94555

(Address of Principal Executive Offices)

 

(Zip Code)

 

510-284-6500

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

        o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

        o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

        o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

        o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 1.01               Entry into a Material Definitive Agreement

 

                On March 18, 2005, Abgenix, Inc. (the “Company”) and Patrick M. Murphy entered into a separation agreement (the “Agreement”) in connection with the transition of Mr. Murphy’s responsibilities as Senior Vice President, Production Services to an interim replacement while the company identifies a permanent successor.  Pursuant to the Agreement, the Company and Mr. Murphy have mutually agreed to a transition in which Mr. Murphy will continue providing services as a full-time employee of the Company, with the title of Senior Vice President, and will assist in performing his current job functions, facilitating the transfer of those duties and engaging in special projects.  Through August 31, 2005, Mr. Murphy will continue to receive the same salary and benefits as he was receiving immediately prior to his entry into the Agreement.  From August 31, 2005 through February 28, 2006, Mr. Murphy will be paid at the same rate for consulting services to the Company.  In addition, the Company will make COBRA payments on Mr. Murphy’s behalf and currently granted stock options will continue to vest during this period.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ABGENIX, INC.

 

 

 

 

Dated:  March 23, 2005

By:

/s/ H. Ward Wolff

 

 

H. Ward Wolff

Chief Financial Officer and

Senior Vice President, Finance

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----